Livestock and aquatic species health and disease prevention.

MVMD’s patented Quicksol™️ solubility technology enhances new and existing compounds in the macrocyclic drug class that focus on improving livestock and aquatic species disease prevention and nutrition.  

Improving Animal and Fish Farming for a Sustainable Food Supply

MVMD works with our partners to improve the health and productivity of animal and fish farming operations to support improved global human food supply chains.

Soluvec™ 1%.  Soluvec™ 1%  is an innovative, proprietary formulation of Ivermectin (IVM) made using MVMD’s patented Quicksol™ solubilization technique. Soluvec™ 1% is a highly soluble patented formulation of Ivermectin complexed with a cyclodextrin without any ionic excipients. The formulation is designed to provide a safer and more effective solution that can be administered in different parenteral routes across a variety of animal species.

Soluvec 1% incorporates non-organic excipients such as polysorbates that are safer to use, unlike current commercially available formulations which use solvents such as propylene glycol and glycerol formal, which causes pain and reaction at the injection site and have poorer absorption.

Revolutionizing Ivermectin Delivery with Soluvec™ 1%

Soluvec™ 1% is formulated to be administered at higher concentrations with a lower dose volume and provide the benefits of higher bioavailability compared to other commercially available formulations.

When Less is 


Introduced in 1981, Ivermectin has been studied for its dose-dependent pharmacokinetics across multiple administration routes. Depending on the species, the medication can be administered orally, intramuscularly (IM), subcutaneously (SC), or topically. The area under the curve (AUC) grows linearly when the dose increases, showing that pharmacokinetic characteristics are dose dependent.

MVMD’s Soluvec™ 1% has a solubility approximately 2,500 times greater than free Ivermectin. In numerous third-party conducted trials, when administered via intramuscular and subcutaneous routes, Soluvec™ 1% increased drug exposure, peak levels, and extended the duration of Ivermectin exposure in husbandry animals compared to commercially available Ivermectin in subcutaneous, intramuscular, and oral forms.


More Soluble Than Generic Ivermectin


IVM Exposure is 7x Higher

Farmed Fish Application. Farmed fish trials were conducted on Indian Catfish, Pangas, Common Carp, Tilapia, and Rui (Ruho) fish species. One group received Soluvec™ 1% coated standard fishfeed, while the control group received non-Soluvec™ 1% standard fish feed.

The results showed increased average daily growth, reduced mortality, and an overall net average increase in net production of 145%. The feed conversion ratio also improved by an average of 16% for all fish species treated with Soluvec™ 1% coated fish feed compared to those receiving non-Soluvec™ 1% coated fish feed, indicating improved efficiency in biomass production.



Compared to traditional methods, Soluvec™ demonstrated significant enhancement inIvermectin solubilization and bioavailability. 

The published peer-reviewed study in the journal, Therapeutic Delivery, highlights the benefits of MVMD’s patented Soluvec™ formulation, a novel, solvent-free aqueous Ivermectin invention.

Improved Solubility with Soluvec™

In the resolubilized product, Soluvec™, Ivermectin was present as a mixof 28.0 nm particles and polysorbate-solubilized free Ivermectin. The totalconcentration was approximately 2,500 times greater than that of freeIvermectin in water. 


IVM Exposure Seven Times Higher

In beagle dogs treated parenterally with Soluvec (subcutaneous or intramuscular dosing), total exposure of Ivermectin was ∼seven-times higher than in dogs receiving a non-solubilized Ivermectin tablet of the same dose orally.

Increased Duration of Exposure

Peak levels were higher and, most importantly for ease of treatment, duration of exposure was reliably greater with parenteral dosing; all Soluvec-treated animals had detectable IVM at 48 h, versus none of the non-solublized Ivermectin orally dosed animals.

Lower Doses Possible

Enhanced bioavailability of IVM in Soluvec™ suggests that a lower dose may achieve the desired therapeutic effects, potentially leading to reduced treatment costs and fewer side effects.

Safety Profile

Research underscores favourable safety profile of Soluvec™, with minimal side effects generally observed in test subjects.

Potential Human and Livestock Applications

The results point to the possibility of easier treatment regimens and improved therapeutic outcomes not just for livestock but potentially for humans as well.

Read the Soluvec™ Publication on Future Science

Access the article “Physical and Pharmacokinetic Characterization of Soluvec™, a novel, solvent-free aqueous Ivermectin formulation" here.

Read Publication

Beyond Animal Husbandry...

While MVMD’s current commercialization is focused on animal husbandry disease prevention, the solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a potential candidate for human injection.  MVMD has plans to further evaluate the human applications in future R&D phases.

Our Biotech Applications

The well-being of humans, animals, and agriculture are a symbiotic ecosystem. The ecosystem must come together and work together to optimize our planet’s resources. At MVMD, we actively invest in and collaborate on pioneering biotechnologies that have the potential to revolutionize human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health.

Subscribe to Updates

Stay plugged in on everything MVMD

Thanks for signing up to our updates!

Should you ever want to update your preferences or unsubscribe entirely, you can do so by contacting

Something went wrong while submitting the form... Please try again later.